Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Frequent Hemodialysis Network: Daily Trial
Brief Summary: The Frequent Hemodialysis Network (FHN) Daily Trial is a randomized controlled trial recruiting subjects from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 1 year. Subjects will be randomized to either conventional hemodialysis Daily HD delivered for at least 2.5 hours (typically 3 to 4 hours), 3 days per week, or to more frequent hemodialysis delivered for 1.5 - 2.75 hours, 6 days per week. The study has two co-primary outcomes: 1) a composite of mortality with the change over 12 months in left ventricular mass by magnetic resonance imaging, and 2) a composite of mortality with the change over 12 months in the SF-36 RAND physical health composite (PHC) quality of life scale.


Options:
A: Arm Label: Conventional hemodialysis; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional hemodialysis | Arm Label: Frequent hemodialysis; Type: EXPERIMENTAL; Interventions: Device: Frequent hemodialysis | Intervention Type: DEVICE; Name: Conventional hemodialysis; Assigned to Arm(s): Conventional hemodialysis | Intervention Type: DEVICE; Name: Frequent hemodialysis; Assigned to Arm(s): Frequent hemodialysis
B: Arm Label: Cohort 1 (RO0503821 [0.25/150 1x/week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 2 (RO0503821 [0.25/150 1x/2week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 3 (RO0503821 [0.4/150 1x/week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 4 (RO0503821 [0.4/150 1x/2week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 5 (RO0503821 [0.6/150 1x/week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 6 (RO0503821 [0.6/150 1x/2week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): Cohort 1 (RO0503821 [0.25/150 1x/week]), Cohort 2 (RO0503821 [0.25/150 1x/2week]), Cohort 3 (RO0503821 [0.4/150 1x/week]), Cohort 4 (RO0503821 [0.4/150 1x/2week]), Cohort 5 (RO0503821 [0.6/150 1x/week]), Cohort 6 (RO0503821 [0.6/150 1x/2week])
C: Arm Label: Engagement Interview; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Engagement Interview | Arm Label: Control Visit; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cognitive Behavioral Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Antidepressant Drug Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antidepressant Drug Therapy | Arm Label: Observational Cohort; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Engagement Interview; Assigned to Arm(s): Engagement Interview | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Cognitive Behavioral Therapy | Intervention Type: DRUG; Name: Antidepressant Drug Therapy; Assigned to Arm(s): Antidepressant Drug Therapy
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis; Assigned to Arm(s): Intervention

Answer: A